Molecular Epidemiology, German Cancer Research Center Heidelberg, Germany ; Molecular Biology of Breast Cancer, Department of Gynecology and Obstetrics, University Clinic Heidelberg, Heidelberg, Germany.
Front Genet. 2013 Jun 21;4:116. doi: 10.3389/fgene.2013.00116. eCollection 2013.
In the recent years, circulating microRNAs (miRNAs) have garnered a lot of attention and interest in the field of disease biomarkers. With characteristics such as high stability, low cost, possibility of repeated sampling and minimal invasiveness, circulating miRNAs are ideal for development into diagnostic tests. There have been many studies reported on the potential of circulating miRNAs as early detection, prognostic, and predictive biomarkers in cancer. Here, we have reviewed the application of plasma and serum miRNAs as biomarkers for cancer focusing on epithelial carcinomas [prostate, breast, lung, colorectal, and gastric cancer (GC)] and hematological malignancies (leukemia and lymphoma). We have also addressed the common challenges that need to be overcome to achieve a successful bench to bedside transition.
近年来，循环 microRNAs（miRNAs）在疾病生物标志物领域引起了广泛关注和兴趣。循环 miRNAs 具有稳定性高、成本低、可重复采样和微创性等特点，非常适合开发成为诊断测试。已有许多研究报道了循环 miRNAs 作为癌症早期检测、预后和预测生物标志物的潜力。在这里，我们综述了血浆和血清 miRNAs 作为癌症标志物的应用，重点关注上皮性癌[前列腺癌、乳腺癌、肺癌、结直肠癌和胃癌（GC）]和血液系统恶性肿瘤（白血病和淋巴瘤）。我们还讨论了实现从实验室到临床成功转化需要克服的常见挑战。
